Clinical Trial

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

Name: Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue — clinical trial record (NCT06740526)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-12-13.

Trial Details

NCT Number	NCT06740526
Lead Sponsor	Otsuka Pharmaceutical Development & Commercialization, Inc.
Conditions	IgA Nephropathy
Enrollment	25 participants
Start Date	2024-11-19
Primary Completion	2029-04-17 (estimated)
Study Completion	2029-04-17 (estimated)
Updated on ClinicalTrials.gov	2025-04-06